ClinicalTrials.Veeva

Menu

Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3

Virginia Commonwealth University (VCU) logo

Virginia Commonwealth University (VCU)

Status

Completed

Conditions

Smoking Cessation
Drug Addiction

Treatments

Drug: Nicotine transdermal system
Other: Nicotine containing cigarette
Drug: nicotine transdermal system
Other: Placebo cigarette

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT00390559
R01DA011082 (U.S. NIH Grant/Contract)
R01-11082-3 DPMC
NIDA-11082-3

Details and patient eligibility

About

Treatment studies have demonstrated that current smoking cessation techniques are less effective for women. The purpose of this study is to determine the role that gender plays in the effectiveness of nicotine replacement therapy. In addition, the purpose of this study is to determine whether men and women differ in their response to smoking-related stimuli (e.g., taste or smell of a lit cigarette). Conclusions drawn from this study may help to improve cessation interventions for all smokers, particularly women.

Full description

Currently,about 70 percent of smokers who try to quit by using smoking cessation treatments are unsuccessful. Treatment studies have demonstrated that current smoking cessation techniques are less effective for women. There is no clear explanation for this difference, but it may involve a differential response to nicotine replacement treatments (NRTs) and/or smoking-related stimuli. For women, NRT may be less effective at suppressing withdrawal or blunting the effects of smoking during a quit attempt. Women may also be more sensitive to smoking-related stimuli, suc has the taste, sight, or smell of cigarette smoke. Tailoring treatments to the separate needs of smoker subgroups , such as men and women, my produce better cessation outcomes. The purpose of this study is to assess whether men and women differ in the their response to NRT (i.e., transdermal nicotine) and smoking-related stimuli.

Participants in this double-blind, dose-comparison study will complete separate sessions in random order.

Each session will last approximately 6.5 hours and will correspond to a transdermal patch dose (0 or 21mg) and cigarette type (denicotinized and nicotinized). Objectively verified cigarette abstinence will be required before each session. Sessions will occur at least 48 hours apart to avoid carryover. At the beginning of each session a patch will be placed on the participant's back and at 4, 5, and 6 hours after patch application the participant will smoke a cigarette (all identifying marking on the cigarette will be covered for blinding purposes). Physiological, subjective, cognitive, and smoking behavior outcomes will be collected during study visits.

Enrollment

80 patients

Sex

All

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria include, but are not limited to:

18-50 years of age Smokes 15 cigarettes/day for at least 2 years Healthy (as determined by a brief study physical with medical doctor) Displays understanding of cognitive tasks.

Exclusion Criteria include, but are not limited to:

History of chronic health problems or psychiatric conditions History of cardiovascular disease, low or high blood pressure, seizures, head injuries requiring hospital care, peptic ulcer, or diabetes Pregnancy (tested by urinalysis) Scores greater than 17 on the Beck Depression Inventory Lack of a high school degree or GED

Trial design

Primary purpose

Basic Science

Allocation

Non-Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

80 participants in 4 patient groups

ActiveP/ActiveC
Experimental group
Description:
21 mg patch/Nicotine-containing cigarette
Treatment:
Other: Nicotine containing cigarette
Drug: nicotine transdermal system
PlaceboP/ActiveC
Experimental group
Description:
0 mg patch/nicotine-containing cigarette
Treatment:
Drug: Nicotine transdermal system
Other: Nicotine containing cigarette
Active P/PlaceboC
Experimental group
Description:
21 mg patch/no nicotine cigarette
Treatment:
Drug: nicotine transdermal system
Other: Placebo cigarette
PlaceboP/PlaceboC
Experimental group
Description:
0 mg patch/no nicotine cigarette
Treatment:
Drug: Nicotine transdermal system
Other: Placebo cigarette

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems